ClinicalTrials.gg
RecruitingNCT05908331MAGICAL ISRUpdated Feb 25, 2025

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

An interventional study of Sirolimus Drug Coated Balloon and Plan balloon Angioplasty (POBA) in In-Stent Restenosis, Cardiovascular Diseases and Coronary Artery Disease, sponsored by Concept Medical Inc.. Recruiting at 28 sites in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Primary conditionCoronary Artery DiseaseRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Concept Medical Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Planned enrollment
155th of 745
492 · median 107
Started
2024
with 35 others
No phase
352 of 1,104
41 open now
Primary completion
2025-09
later than 14 of 141 live
Registered
998th of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 155th largest by planned enrollment of the 745 interventional ones that give a count, is one of 36 that started in 2024, is one of 352 with no phase, reaches primary completion later than 14 of the 141 other live ones, and was the 998th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis.

Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a maximum of 50 study sites located in the United States.

The goal is to establish the safety and efficacy of the MagicTouch™ sirolimus- coated balloon in treatment of coronary in-stent restenosis (ISR).

Read the detailed description

All subjects providing informed consent will have their medical history reviewed and will undergo a physical examination, laboratory screen, and a standardized 12-lead ECG within 7 days of procedure. Women of childbearing potential will have a pregnancy test within one week prior to the procedure. If subjects meet the inclusion and exclusion criteria of the study, they will be randomized to one of two treatment groups, and will then undergo treatment with MagicTouch™ sirolimus-coated balloon or POBA of the target ISR lesion, per trial protocol.

One pre-procedure and all post-procedure biomarker blood draws will be sent to a central core laboratory for analysis of troponin T. Evaluation of post-procedural biomarker blood draws in local laboratories are not mandated but may be performed as part of standard of care.

During the index hospitalization, patients will undergo a clinical assessment and 12-lead ECG; and they will have cardiac biomarkers drawn before the intervention to establish baseline biomarker level and confirmation that the biomarkers are falling. At least one post procedure biomarker (core lab) will be drawn at a minimum of 4 hours after PCI as part of the assessment of periprocedural myocardial infarction and significant periprocedural myocardial injury (at 6-8 hour intervals depending on whether the patient remains admitted). If no procedural complications have occurred and there are no signs of ischemia on post-procedure ECG or clinical assessment, the patient may be discharged per local practice and no additional biomarker levels need to be drawn (beyond the protocol-mandated core laboratory draw at a minimum of 4 hours). If the patient remains admitted cardiac biomarkers (core lab) should be drawn every 6-8 hours until at least 2 total post-procedural core laboratory biomarker draws have passed or clinical standard-based biomarker levels have peaked per local labs or the patient is discharged.

After hospital discharge, subjects will be followed at 30 days (+1 week), 6 months (+2 weeks), and 12 months (+1 month) and then 24, 36, 48 and 60 months (+1 month) post procedure. Yearly vital status information will be collected by telephone follow-up. At the 12-month visit, subjects will undergo 12-lead ECG, blood count, coagulation profile and blood chemistry tests. New and ongoing AEs and concomitant medications will also be assessed.

All elective angiograms performed on the target vessel during the 12-month follow-up period should be preceded by a physician evaluation, during which the physician will indicate whether the subject's clinical status warrants revascularization, i.e. the subject has clinical evidence of ischemia. All films, including unscheduled angiograms, are to be sent to the angiographic core laboratory for review. The angiographic core laboratory will be blinded.

03

Conditions studied

  • In-Stent Restenosis
  • Cardiovascular Diseases
  • Coronary Artery Disease

Browse trials for

Keywords

  • Drug coated balloon
  • Sirolimus coated balloon
  • ISR
  • Magic Touch
  • SCB
  • Concept Medical
  • MAGICAL ISR
04

In context

Coronary Artery Disease Reclassified

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 492 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Concept Medical Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is at least 18 years old
  2. Subject (or legal guardian) understands the trial requirements and treatment procedures and provides written prior to any trial-specific tests or treatment
  3. Patient with an indication for PCI due to suspected in-stent restenosis
  4. Non-target lesion PCI are allowed in non-target vessels to be treated with approved interventional devices prior to randomization as follows:

Angiographic Inclusion Criteria:

  1. In-stent restenosis after drug-eluting stent implantation(s) in the target lesion (i.e. single and multiple stent layer ISR cases are eligible)
  2. Target lesion must have visually estimated stenosis ≥50% and less than 100% diameter stenosis in symptomatic patients; or a visually estimated target lesion diameter stenosis of ≥70%, or by evidence of ischemia by coronary physiology (fractional flow reserve [FFR] ≤0.80 or non-hyperemic pressure ratio [NHPR] ≤0.89) in absence of symptoms
  3. Successful lesion preparation (residual stenosis \<30%), without complications (no or slow flow, flow-limiting dissection, perforation, distal embolization) and without plan for stenting
  4. Target lesion in a native coronary artery
  5. Thrombolysis In Myocardial Infartction (TIMI) grade flow ≥1 in target lesion
  6. Target reference vessel diameter (visual estimation) >2.0 and ≤4.0 mm
  7. Target lesion length (including tandem lesions) ≤36.0 mm (visual estimation) and can be covered by only one balloon
  8. One ISR target lesion (overlapping stents are allowed) to be treated per patient and in single major coronary artery or side branch (reference vessel diameter >2.0 mm)
  9. Other coronary lesions (ISR or non-ISR) in non-target vessel are allowed and may be treated by any approved interventional device, but must be treated successfully prior to randomization

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria (all must be absent for the patient to be eligible):

  1. STEMI within 72 hours of presentation to the first treating hospital, whether a transfer facility or the study hospital
  2. NSTEACS in whom the biomarkers have not peaked
  3. PCI within the 24 hours prior to the index procedure (not including PCI performed in non-target lesions during the index procedure)
  4. Prior DCB treatment (coronary or off-label peripheral) of target lesion ISR
  5. Cardiogenic shock (defined as persistent hypotension [systolic blood pressure \<90 mm Hg] or requiring vasoactive or hemodynamic support, including IABP)
  6. Subject is intubated
  7. Known \<30%
  8. Relative or absolute to DAPT for at least 1 month (e.g., planned surgeries that cannot be delayed)
  9. Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor
  10. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath
  11. \<9 g/dL
  12. count \<100,000 cells/mm3 or >700,000 cells/mm3
  13. White blood cell count \<3,000 cells/mm3
  14. Active infection undergoing treatment
  15. liver disease
  16. Renal insufficiency as defined by estimated (eGFR) to be \<30ml/min by the MDRD formula
  17. Active peptic ulcer or active bleeding from any site
  18. Bleeding from any site requiring active medical attention within the prior 8 weeks
  19. History of bleeding diathesis or coagulopathy or likely to refuse blood transfusions
  20. Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA
  21. Known allergy to the study device components or protocol-required concomitant medications:

    • sirolimus (as well as other limus drugs, analogues, or similar compounds), aspirin, clopidogrel and prasugrel and ticagrelor, heparin and bivalirudin, or iodinated contrast that cannot be adequately pre-medicated
  22. Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduce to \<24 months (e.g. cancer, heart failure, lung disease, severe valvular disease)
  23. Patient is participating in or plans to participate in any other drug or device trial that has not reached its primary endpoint
  24. Women who are pregnant or breastfeeding (women of must have a negative pregnancy test within one week before index procedure)
  25. Women who intend to become pregnant within 12 months after the index procedure
  26. Patient has received an organ transplant or is on a waiting list for an organ transplant
  27. Patient has received chemotherapy within 30 days before the index procedure or scheduled to receive chemotherapy any time after the index procedure
  28. Patient is receiving oral or intravenous therapy or has known life-limiting immunosuppressive or disease. Inhaled and steroid use for contrast- allergy prophylaxis or treatment are allowed

Angiographic Exclusion Criteria (visual estimate) (all must be absent for the patient to be eligible):

  1. More than 1 ISR lesion in the target vessel in segments that cannot be treated by a single 40mm length DCB (see Angiographic Inclusions #5 and #6 above)
  2. ISR lesion in the target vessel in a segment that corresponds to a previously established/documented bare metal stent (BMS)
  3. Unprotected left main lesions >50% or left main intervention
  4. Primary PCI for STEMI
  5. Coronary artery disease judged more suitable for surgical revascularization per guidelines and local heart team discussion
  6. Another lesion in either the target vessel or non-target vessel is present that requires or has a high probability of requiring PCI within 12 months after the index procedure
  7. Prior brachytherapy or DCB treatment of target lesion
  8. Target lesion is a bifurcation restenosis involving both branches of a bifurcation in which the side branch reference vessel diameter is >2.0 mm
  9. Target lesions located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft
  10. Target lesion contains large thrombus
  11. Target lesion is heavily calcified
  12. Target lesion is a chronic total occlusion (or subtotal) without adequate lesion preparation.* Total and subtotal occlusions may be enrolled assuming they can be crossed with a wire and demonstrate TIMI grade 3 flow at the time of randomization.
  13. Diffuse distal disease to target lesion with impaired runoff
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
492 participants (estimated)

Study arms

  • Experimental
    MagicTouch Sirolimus-Coated Balloon

    Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.

    Device: Sirolimus Drug Coated Balloon

  • Active comparator
    POBA

    plain old balloon angioplasty

    Device: Plan balloon Angioplasty (POBA)

Interventions

  • DeviceSirolimus Drug Coated Balloon

    Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.

  • DevicePlan balloon Angioplasty (POBA)

    Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis

07

What researchers measure

Primary outcomes

  1. TLF (Target Lesion Failure)

    The composite rate of cardiac death, target-vessel MI (Myocardial Infarction) or ischemia-driven TLR (Target Lesion Revascularization)

    Time frame: 12 months

Secondary outcomes

  1. MACE (Major adverse cardiovascular events)

    composite of cardiovascular mortality, any MI (Myocardial Infarction), and ID-TLR (Ischemia-Driven Target Lesion Revascularization)

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  2. TVF (Target vessel failure)

    composite of cardiovascular mortality, ID-TVR (Ischemia-Driven Target Vessel Revascularization), and TV-MI (Target Vessel Myocardial Infarction)

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  3. Any revascularization

    any repeat PCI or CABG

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  4. ID-TLR (Ischemia-Driven Target Lesion Revascularization)

    Repeat revascularization of the target lesion due to recurrent ischemia

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  5. TLR (Target Lesion Revascularization)

    Repeat revascularization of the target lesion

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  6. ID-TVR (Ischemia-Driven Target Vessel Revascularization)

    Repeat revascularization of the target vessel due to recurrent ischemia

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  7. TVR (Target Vessel Revascularization)

    Repeat revascularization of the target vessel

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  8. All-cause mortality

    Death from any cause

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  9. Cardiovascular mortality

    Death due to coronary artery disease or complications of coronary treatment

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  10. Any MI (Myocardial Infarction)

    Any Myocardial Infarction

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  11. TV-MI (Target Vessel Myocardial Infarction)

    Myocardial Infarction related to the target vessel

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  12. Q-wave MI (Myocardial Infarction)

    Myocardial Infarction demonstrated by new pathological Q waves on ECG

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  13. Non-Q-wave MI (Myocardial Infarction)

    Myocardial Infarction not demonstrated by new pathological Q waves on ECG

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  14. Cardiovascular mortality or MI (Myocardial Infarction)

    Either cardiovascular death or any Myocardial Infarction

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  15. All-cause mortality or MI (Myocardial Infarction)

    Either death from any cause or any Myocardial Infarction

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  16. All-cause mortality, MI (Myocardial Infarction), or TVR (Target Vessel Revascularization)

    Death from any cause, any Myocardial Infarction, or Target Vessel Revascularization

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  17. Any definite or probable target lesion stent thrombosis by ARC (Academic Research Consortium) criteria

    Definite or probable stent thrombosis in the target lesion according to the ARC (Academic Research Consortium) definition

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  18. Probable target lesion stent thrombosis by ARC (Academic Research Consortium) criteria

    Probable stent thrombosis in the target lesion according to the ARC definition

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  19. Definite target lesion stent thrombosis by ARC (Academic Research Consortium) criteria

    Definite stent thrombosis in the target lesion according to the ARC definition

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  20. BARC (Bleeding Academic Research Consortium) type 3-5 bleeding

    Significant or severe bleeding according to the BARC definition

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

  21. Procedure Success

    ability to deliver the device and achieve a less than 30% residual stenosis by QCA (quantitative coronary angiography) without major complication or bailout stenting

    Time frame: 30 days and 6, 12, 24, 36, 48, and 60 months

Other outcomes

  1. Angina as assessed by SAQ-7 (Seattle Angina Questionnaire)

    Quality of Life Endpoint, Angina will be assessed at these specified timepoints and prior to any invasive procedure

    Time frame: 30 days, 6, 12, 24, 36, 48 and 60 months

08

Study locations

25 of 28 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2025, 17 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 18, 2023
StartActual
Apr 16, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Jul 2028
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908331
Lead sponsor
Concept Medical Inc.
Collaborators
Cardiovascular Research Foundation, New York
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Apr 16, 2024
Primary completion
Sep 2025 (estimated)
Completion
Jul 2028 (estimated)
Last update
Feb 25, 2025

Study contacts

Dario Gattuso
Contact
dario@conceptmedical.com
+393292467132
Farhana Siddique
Contact
farhana@conceptmedical.com
+919725495366

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion